Lee Caffin is a UK Patent Attorney and US Patent Agent, having also passed the European Qualifying Examination for Professional Representatives before the European Patent Office in 1990. Lee has an extensive background and experience in IP matters in life sciences, and focuses his practice on developing company intellectual property positions as strategic assets for growth, defense and/or licensing. Lee has worked in the US and UK in senior roles for major pharmaceutical companies including Glaxo, Sanofi, Takeda and, most recently, Abbott, where he held the positions of DVP of Global IP Strategy and Global Head of Pharmaceutical Patents. An expert in licensing and lifecycle management, Lee had led teams in numerous significant contract negotiations, including one for the $3.5B purchase by Abbott of Kos Pharmaceuticals. Lee also has a very good knowledge of regulatory frameworks relating to Hatch-Waxman and generic abbreviated new drug application (ANDA) activities, and has helped innovators and generic companies plot global strategies to, respectively, defend brand products and introduce generics.